{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Belite Bio, Inc"},"Symbol":{"label":"Symbol","value":"BLTE"},"Address":{"label":"Address","value":"5820 OBERLIN DRIVE,SUITE 101 SUITE 475, SAN DIEGO, California, 92121, United States"},"Phone":{"label":"Phone","value":"+1 858 246-6240"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout."},"CompanyUrl":{"label":"Company Url","value":"https://www.belitebio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Hendrik P. N. Scholl","title":"Chief Medical Officer"},{"name":"Nathan L. Mata","title":"Chief Scientific Officer"},{"name":"Yue Hsin Lin","title":"Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}